EUCTR2020-000097-15-SE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis - TRANSFORM-1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject = 18 years of age.
- •Subject with a documented diagnosis of primary myelofibrosis (MF) or secondary MF (post polycythemia vera [PPV] -MF or post essential thrombocythemia [PET] – MF) as defined by the World Health Organization classification.
- •Subject must be able to complete the Myelofibrosis Symptom Assessment Form (MFSAF) on at least 4 out of the 7 days immediately preceding the date of randomization.
- •- Subject classified as intermediate-2 or high-risk MF as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).
- •Subject has splenomegaly defined as spleen palpation measurement = 5 cm below costal margin or spleen volume = 450 cm^3 as assessed centrally by MRI or CT scan.
- •Subject has at least 2 symptoms measurable (score = 3) or a total score of = 12, as measured by the MFSAF v4.0.
- •Subject with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 92
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 138
排除标准
- •Subject must not have received prior treatment with a JAK-2 inhibitor.
- •Subject must not have received prior treatment with a BH3-mimetic compound or bromodomain and extra-terminal motif (BET) inhibitor.
- •Subject must not be eligible for stem cell transplantation at time of study entry due to age, comorbidities, or unfit for unrelated or unmatched donor transplant and other criteria per National
- •Comprehensive Cancer Network guidelines.
- •Subject must not receive medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period.
研究者
相似试验
进行中（未招募）
1 期
A study to assess the benefit of treatment beyond progression with enzalutamide in men who are starting treatment with docetaxel after worsening of their prostate cancer when taking enzalutamide aloneMetastatic Castrate Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004711-50-BEAstellas Pharma Europe Ltd650
进行中（未招募）
不适用
A Study of LY2835219 Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-FREli Lilly and Company550
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168, a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).on-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvementMedDRA version: 17.0Level: PTClassification code 10047115Term: VasculitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-001222-15-SEChemoCentryx, Inc.60
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular CoagulatioSepsis and disseminated intravascular coagulation.MedDRA version: 9.1 Level: LLT Classification code 10040047 Term: SepsisMedDRA version: 9.1 Level: LLT Classification code 10013442 Term: Disseminated intravascular coagulationEUCTR2007-002035-81-GBArtisan Pharma, Inc.800
进行中（未招募）
1 期
A Study of abemaciclib Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-DEEli Lilly and Company710